Neuroendocrine function in schizophrenia.
Endocrine parameters were studied in 64 male chronic hebephrenic schizophrenics. The results indicate deficiency of the pituitary-gonadal function, increased PRL responses to TRH stimulation, impaired GH responses to successive stimuli, impaired insulin-glucose metabolism, which is indicative of a hypothalamic noradrenaline deficiency. Treatment with catecholamine agonists improved the behavioural affective state in a small group of patients. Studies of dopamine-receptor sensitivity in a group of hebephrenics and paranoids revealed the existence of 2 genetically divided groups, the HLA negative and HLA positive, of which only the first showed signs of dopamine-receptor supersensitivity.
D000293:Adolescent; D000328:Adult; D001058:Apomorphine / Q000494:pharmacology; D001786:Blood Glucose / Q000032:analysis; D002230:Carbidopa / Q000494:pharmacology; D005640:Follicle Stimulating Hormone / Q000502:physiology; D013006:Growth Hormone / Q000502:physiology; D006220:Haloperidol / Q000494:pharmacology; D006801:Humans; D007328:Insulin / Q000502:physiology; D007980:Levodopa / Q000494:pharmacology; D007986:Luteinizing Hormone / Q000502:physiology; D008297:Male; D008875:Middle Aged; D011388:Prolactin / Q000502:physiology; D012562:Schizophrenia, Disorganized / Q000503:physiopathology*; D013739:Testosterone / Q000502:physiology; D013973:Thyrotropin-Releasing Hormone / Q000494:pharmacology
D001786:Blood Glucose; D007328:Insulin; D013739:Testosterone; D007980:Levodopa; D013973:Thyrotropin-Releasing Hormone; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013006:Growth Hormone; D006220:Haloperidol; D002230:Carbidopa; D001058:Apomorphine